Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
Medtronic
Express Scripts
Dow

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202497

See Plans and Pricing

« Back to Dashboard

NDA 202497 describes MARQIBO KIT, which is a drug marketed by Acrotech and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the MARQIBO KIT profile page.

The generic ingredient in MARQIBO KIT is vincristine sulfate. There are thirteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the vincristine sulfate profile page.
Summary for 202497
Tradename:MARQIBO KIT
Applicant:Acrotech
Ingredient:vincristine sulfate
Patents:3
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 202497
Suppliers and Packaging for NDA: 202497
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497 NDA Talon Therapeutics, Inc. 20536-322 20536-322-01 1 KIT in 1 CARTON (20536-322-01) * 1 mL in 1 VIAL, GLASS (20536-324-01) * 25 mL in 1 VIAL, GLASS (20536-325-01) * 5 mL in 1 VIAL, GLASS (20536-323-01)
MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497 NDA Acrotech Biopharma LLC 72893-008 72893-008-03 1 KIT in 1 CARTON (72893-008-03) * 1 mL in 1 VIAL, GLASS (72893-011-05) * 25 mL in 1 VIAL, GLASS (72893-010-05) * 5 mL in 1 VIAL, GLASS (72893-012-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE, LIPOSOMAL;INTRAVENOUSStrength5MG/5ML (1MG/ML)
Approval Date:Aug 9, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 9, 2019
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
Patent:  Start TrialPatent Expiration:Mar 31, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
Patent:  Start TrialPatent Expiration:Sep 25, 2020Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 202497

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012   Start Trial   Start Trial
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012   Start Trial   Start Trial
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.